The clinical utility of aflibercept for diabetic macular edema
Michael W StewartDepartment of Ophthalmology, Mayo School of Medicine, Jacksonville, FL, USAAbstract: The treatment of center-involving diabetic macular edema (DME) has improved because of the proven efficacy of drugs that inhibit the effects of vascular endothelial growth factor (VEGF). The newest...
Main Author: | Stewart MW |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2015-09-01
|
Series: | Diabetes, Metabolic Syndrome and Obesity : Targets and Therapy |
Online Access: | https://www.dovepress.com/the-clinical-utility-of-aflibercept-for-diabetic-macular-edema-peer-reviewed-article-DMSO |
Similar Items
-
Aflibercept compared with dexamethasone in diabetic macular edema
by: Rodolfo Garretón, et al.
Published: (2021-05-01) -
The role of aflibercept in the management of diabetic macular edema
by: Chang AA, et al.
Published: (2015-08-01) -
The efficacy and safety of aflibercept and conbercept in diabetic macular edema
by: Cai S, et al.
Published: (2018-10-01) -
Effect of intravitreal aflibercept on recalcitrant diabetic macular edema
by: Kendra A. Klein, et al.
Published: (2017-04-01) -
Intravitreal ziv-aflibercept for macular edema following retinal vein occlusion
by: Paulose R, et al.
Published: (2016-09-01)